In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Lautenschlaeger, Tim ^a,b   Perry, James ^a,b   Peereboom, David ^c   Li, Bin ^a,b   Ibrahim, Ahmed ^a,b,d   Huebner, Alexander ^a,b   Meng, Wei ^a,b   White, Julia ^a   Chakravarti, Arnab ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Brain metastasis; Breast cancer; Cilengitide; Radiation

Indexed keywords

BETA3 INTEGRIN; BETA5 INTEGRIN; CILENGITIDE;

APOPTOSIS; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; IN VITRO STUDY; RADIOSENSITIZATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN BETA CHAINS; INTEGRIN BETA3; NEOPLASM METASTASIS; SNAKE VENOMS;

EID: 84886008032     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-246     Document Type: Article

References (23)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22:2865-2872. 10.1200/JCO.2004.12.149, 15254054.
2. Sharma M, Abraham J. CNS metastasis in primary breast cancer. Expert Rev Anticancer Ther 2007, 7:1561-1566. 10.1586/14737140.7.11.1561, 18020924.
3. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012, 30:419-425. 10.1200/JCO.2011.38.0527, 3269967, 22203767.
4. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
5. Silva R, D'Amico G, Hodivala-Dilke KM, Reynolds LE. Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 2008, 28:1703-1713. 10.1161/ATVBAHA.108.172015, 18658045.
6. Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, Anderson RL. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 2006, 8:R20. 10.1186/bcr1398, 1557720, 16608535.
7. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresh DA, Black PM. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001, 49:380-389. discussion 390.
8. Adachi M, Taki T, Higashiyama M, Kohno N, Inufusa H, Miyake M. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res 2000, 6:96-101.
9. Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002, 87:836-845.
10. Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C, Dedhar S. alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 2003, 22:1688-1702. 10.1038/sj.onc.1206347, 12642872.
11. Lorger M, Krueger JS, O'Neal M, Staflin K, Felding-Habermann B. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci U S A 2009, 106:10666-10671. 10.1073/pnas.0903035106, 2697113, 19541645.
12. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010, 10:753-768. 10.2174/187152010794728639, 3267166, 21269250.
13. Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I, Schuch G. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 2008, 27:86-9966-27-86.
14. Bretschi M, Merz M, Komljenovic D, Berger MR, Semmler W, Bauerle T. Cilengitide inhibits metastatic bone colonization in a nude rat model. Oncol Rep 2011, 26:843-851.
15. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 2006, 65:1536-1543. 10.1016/j.ijrobp.2006.04.036, 16863930.
16. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002, 62:4263-4272.
17. Steele JG, Dalton BA, Underwood PA, Smith GJ. Differences in adhesion to tissue culture plastic of clonally related transformed and control sublines from an epithelial cell strain. J Cell Sci 1991, 100(Pt 1):195-203.
18. Keely PJ. Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. J Mammary Gland Biol Neoplasia 2011, 16:205-219. 10.1007/s10911-011-9226-0, 21822945.
19. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011, 36:320-328. 10.1016/j.tibs.2011.03.006, 3112285, 21531565.
20. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003, 22:5866-5875. 10.1038/sj.onc.1206699, 12947393.
21. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer 2009, 124:2719-2727. 10.1002/ijc.24240, 19199360.
22. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 2009, 11:747-756. 10.1215/15228517-2009-012, 2802395, 19221171.
23. Palmieri D, Smith QR, Lockman PR, Bronder J, Gril B, Chambers AF, Weil RJ, Steeg PS. Brain metastases of breast cancer. Breast Dis 2006, 26:139-147.